India's CDMO Sector Poised for Growth as Pharma Diversifies Beyond China

The global pharmaceutical supply chain is undergoing a structural realignment as multinational companies seek to reduce their dependence on China. Indian Contract Development and Manufacturing Organisations (CDMOs) are emerging as the primary beneficiaries of this shift, positioning themselves as trusted, high-quality alternatives for global drugmakers.

India Emerges as the Preferred Global Alternative

The movement away from Chinese manufacturing is not a sudden reaction to recent regulatory scrutiny surrounding giants like WuXi AppTec; rather, it is a transition that began nearly two years ago. According to Sivaramakrishnan Chittor, CFO of Sai Life Sciences, global pharmaceutical companies have already initiated deep engagements with Indian CDMOs to de-risk their supply chains.

The inclusion of Indian entities in strategic regulatory lists has further solidified India's position as the "best bet" for diversification. To capitalize on this, Indian firms are aggressively scaling up operations and committing significant capital expenditure (capex) to meet the rising demand from global innovators.

Sai Life Sciences: Scaling Capacity and Revenue Mix

Sai Life Sciences serves as a bellwether for the industry, currently working with 19 of the top 25 global pharmaceutical companies. The company’s financial trajectory reflects the broader industry trend of deeper integration with "Big Pharma." Over the last four years, the revenue contribution from large global pharmaceutical companies has nearly doubled, rising from 28% to 49%.

To support this growth, Sai Life Sciences has announced a massive expansion plan, earmarking between ₹1,100 crore and ₹1,300 crore for capacity expansion by FY27. This investment will be funded through a combination of internal accruals and manageable debt, ensuring a healthy balance sheet while the company builds out its manufacturing footprint.

Transition from Clinical Supplies to Commercial Manufacturing

A critical evolution in the Indian CDMO landscape is the shift in the type of work being outsourced. Historically, many global firms utilized India primarily for clinical-stage supplies. However, there is a growing trend of moving toward commercial-scale manufacturing within the country.

This shift is evidenced by the strengthening commercial pipeline. Sai Life Sciences reported a significant increase in late-stage development projects, with the number of Phase III and pre-registration molecules growing from six to eleven over the past year. This indicates that global innovators now view Indian facilities as capable of handling high-volume, commercial-grade production.

While the opportunity is landmark, industry leaders caution that the benefits will materialize gradually. Because pharmaceutical manufacturing is heavily governed by strict regulatory approvals and complex product transfer timelines, the shift in manufacturing contracts cannot happen overnight.

Despite the long-term optimism, Sai Life Sciences has maintained a steady revenue growth guidance of 15-20% CAGR. The company expects the second half of the current financial year to be stronger, driven by new capacity additions and improved order visibility as existing capex begins to come online.

Key Takeaways

  • Strategic Diversification: Global pharma companies are actively moving away from China, viewing India as the most reliable alternative for long-term supply chain security.
  • Shift to Commercial Scale: Indian CDMOs are moving beyond clinical research into high-value commercial-scale manufacturing, evidenced by a surge in Phase III molecule projects.
  • Aggressive Infrastructure Investment: Leading players like Sai Life Sciences are investing up to ₹1,300 crore in capacity expansion to meet the anticipated structural demand.